⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Metagenomi Therapeutics, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Metagenomi Therapeutics, Inc.
↗Emeryville, United States
Metagenomi Therapeutics is an in vivo genome editing company that leverages a proprietary, AI-driven metagenomics platform to discover and develop curative genetic medicines. The company's extensive toolbox includes ultra-small nucleases, base editors, and large gene integration systems (such as CAST and RNA-mediated integration) designed to target a wide spectrum of genetic mutations.
The company focuses on developing both wholly-owned assets, such as its lead program MGX-001 for hemophilia A, and partnered programs in cardiometabolic and other therapeutic areas. Headquartered in Emeryville, California, Metagenomi transitioned from a private, VC-backed entity to a public company (NASDAQ: MGX) in 2024.
CLASSIFICATION
SIZE & FINANCIALS
Employees:51-200
Revenue:$22.3M
Founded:2016
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Total Raised:$376M
Investors:Frazier Healthcare Partners, Novo Holdings, Catalio Capital Management, SymBiosis, Leaps by Bayer, Moderna, PFM Health Sciences, Farallon Capital Management
STOCK
Exchange:NASDAQ
Ticker:MGX
Market Cap:$48.2M
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical
Modalities:Gene therapy, Gene editing
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Key Partnerships:Ionis Pharmaceuticals (Cardiometabolic indications), ModernaTX, Inc. (In vivo human therapeutic applications), Affini-T Therapeutics, Inc. (T-cell receptor-based therapies)
COMPETITION
Position:Emerging
Competitors:CRISPR Therapeutics, Editas Medicine, Intellia Therapeutics, Beam Therapeutics, Mammoth Biosciences, Precision BioSciences
LEADERSHIP
Key Executives:
Jian Irish - CEO, President & Director
Mark Leonard - SVP, Technical Development & Operations
Pamela M. Wapnick - CFO
Scientific Founders:Brian Charles Thomas
Board Members:Willard Dere, Eric Bjerkholt, Laurence Reid
LINKS
Website:metagenomi.co
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Metagenomi Therapeutics, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.